Nasdaq
$1.15▼ 2.54%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $644.9MShares out 5.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.9After-hours26.10.10 05:15S-8Offering#●●●#●●●
SL Science Holding Ltd
SL Science Holding Ltd has registered 85,000,000 ordinary shares for its 2026 Share Incentive Plan. These shares are intended for compensation of employees, directors, and consultants, with a proposed maximum offering price of $1.57 per share.…more
$1.15-2.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1After-hours26.10.02 05:30SCHEDULE 13D/AOwnership
SL Science Holding Ltd
Major shareholders Ching-Dong Wang and SL Link Holding Ltd have entered into a joint filing agreement for Schedule 13D regarding SL Science Holding Ltd (SLBT). This filing, dated October 1, 2026, formalizes the legal arrangement for both parties to submit joint disclosures concerning their equity holdings.…more
$1.15-2.54%vs prev closeView filingShare - 10.1After-hours26.10.02 05:304Ownership
SL Science Holding Ltd
Insider Wang Ching-Dong of SL Science Holding Ltd filed a Form 4 on October 1, 2026, reporting a change in beneficial ownership of securities as of September 29, 2026. This filing serves as a standard notification of changes in the insider's equity holdings.…more
$1.15-2.54%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.24Pre-market26.09.24 21:00#●●●#●●●
SL Science Presents Preclinical Data for Glioblastoma Therapy
SL Science presented preclinical data at the Japanese Cancer Association demonstrating that its gamma-delta T cell therapy targets chemotherapy-resistant glioblastoma cells. These findings remain in the early research stage, and clinical safety and efficacy have yet to be established.…more
$1.15-2.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.2After-hours26.09.03 05:10
●●●●●●●● ●●●●● ●●●●●●
SL Science celebrated its first quarter on the Nasdaq by highlighting progress in its Gamma Delta T cell platform and ongoing regulatory efforts. The announcement focuses on clinical development milestones and future potential rather than immediate financial results.…more
$1.15-2.54%vs prev close - 8.27Pre-market26.08.27 21:19
●●●●●●●● ●●●●● ●●●●●●
SL Science's partner, JY BioMed, has filed a Drug Master File with the FDA for exosomes derived from Gamma Delta T cells. This milestone is expected to streamline regulatory processes and support the development of therapies for conditions like glioblastoma.…more
$1.15-2.54%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report